Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

医学 来那度胺 多发性骨髓瘤 耐火材料(行星科学) 肿瘤科 内科学 临床研究阶段 泊马度胺 癌症研究 临床试验 生物 天体生物学
作者
Wen-Ming Chen,Chengcheng Fu,Baijun Fang,Aibin Liang,Zhongjun Xia,Yanjuan He,Jinmiao Lu,Hui Liu,Ming Hou,Zhen Cai,Wei Yang,Siguo Hao,Songfu Jiang,Hongmei Jing,Jing Liu,Xin Du,Rong Fu,Heng Mei,Zunmin Zhu,Yanli Yang
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 4762-4762 被引量:4
标识
DOI:10.1182/blood-2024-204620
摘要

Background Clinical efficacy of B-cell maturation antigen (BCMA) targeting CAR T-cell products in the treatment of relapsed/refractory multiple myeloma (RRMM) can be influenced by patient characteristics such as Age, International Staging System (ISS) stage, and high-risk cytogenetics. Zevorcabtagene autoleucel (zevor-cel) is a fully human, BCMA-targeting autologous CAR T-cell therapy. In the ongoing Phase I/II study LUMMICAR STUDY 1 (NCT03975907), zevor-cel has shown compelling efficacy with an acceptable safety profile in heavily pre-treated patients with RRMM. Here, we conducted subgroup analyses to evaluate the impact of baseline characteristics on the efficacy of zevor-cel in patients treated in the Phase II stage of LUMMICAR STUDY 1. Aims To assess the potential impact of patient characteristics on the clinical efficacy of zevor-cel in RRMM through subgroup analyses. Methods Patients with RRMM who had received at least 3 prior lines of therapy including an immunomodulatory drug and a proteasome inhibitor were enrolled in the study. A single dose of 150 × 106 zevor-cel (target dose of 150 × 106 or 180 × 106 CAR-positive T cells based on body weight of ≤80 kg or >80 kg, respectively) was administered 1 to 2 days after the completion of lymphodepletion. Response was assessed per the international myeloma working group (IMWG) 2016 criteria by an independent review committee (IRC). Subgroups with sample size greater than 20% of the total study population including, Age (<65 years [yrs] versus ≥65 yrs), International Staging System (ISS; I/II versus III), and the presence or absence of high-risk cytogenetics were selected for subgroup analyses. Results Between December 1st, 2020, and March 2nd, 2022, a total of 102 patients were enrolled. Overall, the median age was 59.5 years (range: 38 to 75) with 31 (30.4%) patients aged 65 years or older, 39 (38.2%) patients had ISS Stage III and 61 (59.8%) patients had high-risk cytogenetics. The objective response rate (ORR) was 92.2% (95% CI: 85.13, 96.55) for the whole study population; 73 (71.6%) patients achieved stringent complete response (sCR, n=69) or complete response (CR, n=4), 20 (19.6%) achieved very good partial response (VGPR), 1 (1.0%) achieved partial response (PR). The ORR or the CR/sCR rate was not affected by any of the baseline characteristics tested: In age-based subgroups, ORR and CR/sCR rate for <65yrs versus ≥ 65yrs were 93.0% (66/71) versus 90.3% (28/31) and 71.8% (51/71) versus 71.0% (22/31), respectively. In ISS-based subgroups, ORR and CR/sCR rate for ISS I/II versus ISS III were 89.7% (35/39) versus 93.7% (59/63) and 61.5% (24/39) versus 77.8% (49/63), respectively. Subgroup without high-risk cytogenetics had ORR and CR/sCR rates of 90.2% (37/41) and 73.2% (30/41), respectively, compared to ORR and CR/sCR rate of 93.4% (57/61) and 70.5% (43/61), respectively in patients with high-risk cytogenetics. With a median follow-up of 20.3 (range: 0.4 to 27) months, the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) data were not mature and therefore, 18-month (18m) and estimated 30-month (30m) event free rates were used as efficacy outcomes for subgroup analyses. The DOR, PFS and OS were not impacted by age or ISS. In the age-based subgroups <65yrs versus ≥ 65yrs, 18m DOR rate was 62% versus 60%, 18m PFS rate was 63% versus 58% and the estimated 30m OS rate was 81% versus 77%. In ISS-based subgroups I/II versus III, 18m DOR rate was 57% versus 64%, 18m PFS rate was 58% versus 63% the estimated 30-month OS rate was 76% versus 81%. There was a trend towards favorable outcomes which was seen in patients without high-risk cytogenetics compared to those with high-risk cytogenetics: 18m DOR rate of 66% versus 58%, 18m PFS rate of 69% versus 56% and an estimated 30m OS rate of 85% versus 76%, however, none of these differences were statistically significant. Conclusion The subgroup analyses of the pivotal Phase II stage of LUMMICAR STUDY 1 indicated that the clinical efficacy of zevor-cel is not significantly impacted by baseline characteristics suggesting that even patients with RRMM with poor prognostic factors may benefit from zevor-cel.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风格完成签到,获得积分10
5秒前
5秒前
水煮电吹风的应助被雪山飞龙采纳,获得10
6秒前
醉酒当歌完成签到 ,获得积分10
7秒前
侯子完成签到 ,获得积分10
7秒前
追寻微笑完成签到 ,获得积分10
7秒前
勤劳的唇膏完成签到,获得积分10
11秒前
taowenquan完成签到 ,获得积分10
18秒前
旅行者N0501完成签到,获得积分10
20秒前
灵巧的长颈鹿完成签到,获得积分10
26秒前
怼怼完成签到 ,获得积分10
28秒前
nikki完成签到 ,获得积分10
28秒前
马伯乐完成签到 ,获得积分10
29秒前
Hello的应助被豆豆采纳,获得10
29秒前
33秒前
动人的冷霜完成签到,获得积分10
34秒前
迅速的新竹完成签到,获得积分10
34秒前
Peiqi的应助被雪山飞龙采纳,获得10
37秒前
39秒前
蓝精灵完成签到,获得积分10
41秒前
yuki完成签到 ,获得积分10
41秒前
漾漾的羊完成签到 ,获得积分10
43秒前
dianeil完成签到,获得积分10
51秒前
王不凡完成签到 ,获得积分10
53秒前
LWJ完成签到 ,获得积分10
53秒前
竹舍翁暮雨君完成签到 ,获得积分10
56秒前
机智的孤兰完成签到 ,获得积分10
56秒前
拼搏忆文完成签到,获得积分10
59秒前
康康舞曲完成签到 ,获得积分10
1分钟前
XU博士完成签到,获得积分10
1分钟前
轻歌水越完成签到 ,获得积分10
1分钟前
风趣朝雪完成签到,获得积分10
1分钟前
Robin完成签到 ,获得积分10
1分钟前
一瓣橘子完成签到,获得积分10
1分钟前
kk完成签到,获得积分10
1分钟前
Fan完成签到 ,获得积分0
1分钟前
蔡勇强完成签到 ,获得积分10
1分钟前
bo完成签到 ,获得积分0
1分钟前
lpp完成签到 ,获得积分10
1分钟前
Heby完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012